
Sign up to save your podcasts
Or


David Southwell, CEO of Volastra Therapeutics, shares his insights about leadership in biopharma and how Volastra is working to discover and develop oncology therapeutics targeting chromosomal instability, a vulnerability of cancers.
By John Simboli5
77 ratings
David Southwell, CEO of Volastra Therapeutics, shares his insights about leadership in biopharma and how Volastra is working to discover and develop oncology therapeutics targeting chromosomal instability, a vulnerability of cancers.

3,069 Listeners

1,986 Listeners

1,107 Listeners

2,347 Listeners

948 Listeners

795 Listeners

127 Listeners

336 Listeners

6,105 Listeners

93 Listeners

10,233 Listeners

562 Listeners

153 Listeners

248 Listeners

183 Listeners